| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 4002958 | American Journal of Ophthalmology | 2011 | 9 Pages |
Abstract
AR-12286 was well tolerated and provided clinically and statistically significant ocular hypotensive efficacy in patients with ocular hypertension and glaucoma.
Related Topics
Health Sciences
Medicine and Dentistry
Ophthalmology
Authors
Robert D. Williams, Gary D. Novack, Thomas van Haarlem, Casey Kopczynski, AR-12286 Phase 2A Study Group AR-12286 Phase 2A Study Group,